Tuesday, March 26, 2019 Daily Archives

Manufacturing is the differentiator for CAR-T success, says Allogene

by

Allogene has tweaked the manufacturing process for its allogeneic CAR-T candidate ALLO-501 to produce more robust and consistent product. Since raising $324 million (€283 million) in an initial public offering (IPO) last October, Allogene Therapeutics has announced plans to build a 118,000 square foot cell therapy manufacturing facility in Newark, California and reported its first fourth quarter financials. In the call discussing the latter, the firm’s CEO David Chang told stakeholders that success for chimeric antigen receptor (CAR) T-cell therapies…

March 26, 2019

Celgene deal: ‘Tremendous excitement’ at BMS despite shareholder jitters

by

After assessing over 70 opportunities, Bristol-Myers Squibb insists the proposed $74 billion acquisition of Celgene is the ‘right and best’ option for the firm. Bristol-Myers Squibb (BMS) announced in January it had entered into an agreement to buy Celgene for $74 billion (€65 billion) in what will be the largest megamerger ever in the biopharma space. The deal has been undermined by investor groups, which have described the proposed acquisition as “poorly conceived and ill-advised.†But speaking at the Cowen…

March 26, 2019